Crescent Formulations LimitedUnique Economy
- Crescent is deeply concerned about the growing financial burden on patients, especially in chronic therapy segments like Neurodegenerative Disorders, Psychiatric Abnormalities, Orthopaedics etc
- Neurodegenerative Disorders often associated with the damage & destruction of neurons leads to severe neuropathic pain, loss of memory etc. The cost burden of Neuropathic pain management drugs & Cognitive Enhancer drugs may often lead to abrupt discontinuation of therapy by the patients.
- Similarly, Psychiatry diseases and osteoarthritis poses a serious problem pertaining to quality of life, especially in middle age and elderly people which many a times has a direct impact on life as many patients are either pensioners or dependents.
- Crescent understands the necessity of introducing products which are economical and affordable to such patients. Crescent had initiated many measures which had led to reduced cost of brands viz: Gabacent, Gabarich, Mobinex, Cita S, Rabicent, Arthopan, Kefive Plus etc., which are most economical, than competitors.
